Tourmaline Bio, Inc.
tourmalinebio.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q2 FY2025 10-Q, filed Aug 13, 2025. Its latest SEC filing is a EFFECT from Nov 14, 2025.
10-Q for Q2 FY2025, filed Aug 13, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops pacibekitug, an antibody medicine for patients with cardiovascular inflammation, thyroid eye disease and other immune and inflammatory diseases.
10-K for FY2024, filed Mar 13, 2025We are a late-stage clinical biotechnology company focused on developing transformative medicines that dramatically improve the lives of…View ↗
Our initial product candidate is pacibekitug (also known as TOUR006), a fully human monoclonal antibody that selectively binds to…View ↗
We are pursuing two strategic paths for pacibekitug, the first of which is cardiovascular inflammation. We believe pacibekitug has the…View ↗
Our second strategic path is thyroid eye disease (“TED”). TED is an autoimmune disease characterized by autoantibody-mediated activation of…View ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q2 FY2025, filed Aug 13, 2025
−$23.1MView ↗
- ▲ +32% (Loss)
- vs −$17.5M in Q2 FY2024
-
Oct 28, 2025
Novartis completed its acquisition of Tourmaline
Tourmaline became an indirect wholly owned subsidiary, and its shares were removed from Nasdaq listing.
Sources
8-K, filed Oct 28, 2025
At the Effective Time, the Company became an indirect wholly owned subsidiary of Parent. As a result of Purchaser’s acquisition of the…View ↗
Cell therapy to antibody medicine
The business shifted from a donor-cell therapy for organ transplants and severe disorders to an antibody medicine for cardiovascular inflammation, thyroid eye disease and other immune and inflammatory diseases.
10-K for FY2021, filed Mar 17, 2022 10-K for FY2024, filed Mar 13, 2025We are a late-stage clinical biotechnology company focused on developing transformative medicines that dramatically improve the lives of…View ↗
Our initial product candidate is pacibekitug (also known as TOUR006), a fully human monoclonal antibody that selectively binds to…View ↗
We are pursuing two strategic paths for pacibekitug, the first of which is cardiovascular inflammation. We believe pacibekitug has the…View ↗
Our second strategic path is thyroid eye disease (“TED”). TED is an autoimmune disease characterized by autoantibody-mediated activation of…View ↗
Who Did They Compete With?
Competes with CSL Behring, Novo Nordisk, Roche, Viridian Therapeutics, Acelyrin, Amgen, Sling Therapeutics, Innovent Biologics, Minghui Pharmaceutical, argenx, Immunovant, Harbour BioMed, Lassen Therapeutics, Lundbeck, GenSci, Regeneron, Kriya Therapeutics, Crinetics Pharmaceuticals, Septerna, and Biocad
10-K for FY2024, filed Mar 13, 2025There are multiple IL-6 inhibitors in active clinical development (but not yet approved in the U.S.) including: ARGX-109 (argenx)…View ↗
Loading...
